Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply
MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. WZ reports honoraria for Grunenthal and speaker fees f...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press
2018
|
| Online Access: | https://eprints.nottingham.ac.uk/53706/ |
| _version_ | 1848798975585419264 |
|---|---|
| author | Persson, Monica S.M. Sarmanova, Aliya Doherty, Michael Zhang, Weiya |
| author_facet | Persson, Monica S.M. Sarmanova, Aliya Doherty, Michael Zhang, Weiya |
| author_sort | Persson, Monica S.M. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. WZ reports honoraria for Grunenthal and speaker fees for Bioiberica and Hisun, outside the submitted work. All other authors have declared no conflicts of interest. |
| first_indexed | 2025-11-14T20:28:19Z |
| format | Article |
| id | nottingham-53706 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T20:28:19Z |
| publishDate | 2018 |
| publisher | Oxford University Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-537062019-08-08T04:30:18Z https://eprints.nottingham.ac.uk/53706/ Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply Persson, Monica S.M. Sarmanova, Aliya Doherty, Michael Zhang, Weiya MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. WZ reports honoraria for Grunenthal and speaker fees for Bioiberica and Hisun, outside the submitted work. All other authors have declared no conflicts of interest. Oxford University Press 2018-07-23 Article PeerReviewed application/pdf en https://eprints.nottingham.ac.uk/53706/1/AcceptedManuscript_ReplyDMARDS_Persson_23.07.2018.pdf Persson, Monica S.M., Sarmanova, Aliya, Doherty, Michael and Zhang, Weiya (2018) Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply. Rheumatology . ISSN 1462-0332 (In Press) |
| spellingShingle | Persson, Monica S.M. Sarmanova, Aliya Doherty, Michael Zhang, Weiya Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply |
| title | Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply |
| title_full | Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply |
| title_fullStr | Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply |
| title_full_unstemmed | Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply |
| title_short | Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply |
| title_sort | comment on: conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: reply |
| url | https://eprints.nottingham.ac.uk/53706/ |